<SEC-DOCUMENT>0001144204-15-072256.txt : 20151222
<SEC-HEADER>0001144204-15-072256.hdr.sgml : 20151222
<ACCEPTANCE-DATETIME>20151222160524
ACCESSION NUMBER:		0001144204-15-072256
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20151222
FILED AS OF DATE:		20151222
DATE AS OF CHANGE:		20151222

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIO BLAST PHARMA LTD.
		CENTRAL INDEX KEY:			0001596812
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36578
		FILM NUMBER:		151302248

	BUSINESS ADDRESS:	
		STREET 1:		37 DEREH MENACHEM BEGIN ST.
		STREET 2:		15TH FLOOR
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6522042
		BUSINESS PHONE:		972 (0) 3 7326616

	MAIL ADDRESS:	
		STREET 1:		37 DEREH MENACHEM BEGIN ST.
		STREET 2:		15TH FLOOR
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6522042
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v427593_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">UNITED STATES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SECURITIES AND EXCHANGE COMMISSION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Washington, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form 6-K</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Report of Foreign Private Issuer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Pursuant to Rule 13a-16 or 15d-16</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">under the Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the month of: December 2015 (Report
No. 2)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission file number: 001-36578</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>BIOBLAST PHARMA LTD.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Translation of registrant's name into English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">37 Dereh Menechem Begin St., 15<SUP>th</SUP>
Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Tel Aviv 6522042 Israel</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will
file annual reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Form 20-F &nbsp;<FONT STYLE="font-family: Wingdings">x
</FONT>Form 40-F <FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulations S-T Rule 101(b)(1):_____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulations S-T Rule 101(b)(7):_____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>CONTENTS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Attached hereto as Exhibit 99.1 and incorporated
by reference herein is the Registrant's Notice of Meeting, Proxy Statement and Proxy Card for the  Extraordinary General Meeting of Shareholders
to be held on Wednesday, January 27, 2016 (the &ldquo;<U>Meeting</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Only shareholders of record who hold Ordinary
Shares, nominal value NIS 0.01, of the Registrant at the close of trading on the Nasdaq Global Market on December 28, 2015, will
be entitled to notice of and to vote at the Meeting and any postponements or adjournments thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Notice of Meeting and Proxy Statement
attached to this Form 6-K of the Registrant are incorporated by reference into the registration statement on Form F-3 (File No.
333-206032) and the registration statement on Form S-8 (File No. 333-203114) of the Registrant, filed with the Securities and Exchange
Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or
reports subsequently filed or furnished.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit No.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 13%; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">99.1</FONT></TD>
    <TD STYLE="width: 86%; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Notice of Meeting, Proxy Statement and Proxy Card for the Extraordinary General Meeting of Shareholders to be held on Wednesday, January 27, 2016.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SIGNATURES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%; padding-bottom: 10pt">&nbsp;</TD>
    <TD STYLE="width: 23%; padding-bottom: 10pt">&nbsp;</TD>
    <TD STYLE="width: 47%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>BioBlast Pharma Ltd. </U><BR>
        (Registrant)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><BR>
        <U>By /s/ Colin Foster </U></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 10pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 10pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name: Colin Foster</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 10pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 10pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief Executive Officer and President</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: December 22, 2015</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v427593_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 53px; width: 248px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>BIOBLAST PHARMA LTD.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTICE OF EXTRAORDINARY GENERAL MEETING
OF SHAREHOLDERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notice is hereby given
that an Extraordinary General Meeting of the Shareholders of BioBlast Pharma Ltd. (&ldquo;<B>Company</B>&rdquo;) will be held on
January 27, 2016, at 10:00 a.m. (Israel Time), at the offices of the Company's counsel, Zysman, Aharoni, Gayer &amp; Co., at &quot;<FONT STYLE="background-color: white">Beit
Zion&quot;, 41-45 Rothschild Blvd., 8<SUP>th</SUP> Fl., Tel Aviv 6578401</FONT>, Israel (&ldquo;<B>Meeting</B>&rdquo;), for the
following purposes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify">Approval of amended terms of engagement with Dr. Megiddo.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>Record Date and Right to Vote</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the provisions of Israeli law
and the Company's Articles of Association (&ldquo;<B>Articles</B>&rdquo;), only shareholders of record as of the close of trading
on the Nasdaq Global Market on December 28, 2015 (&ldquo;<B>Record Date</B>&rdquo;) are entitled to attend and vote at the Meeting
and any adjournments or postponements thereof. You are also entitled to notice of the Meeting and to vote at the Meeting if you
held ordinary shares of the Company par value NIS 0.01 per share (&ldquo;<B>Ordinary Shares</B>&rdquo;) through a bank, broker
or other nominee which was one of the Company&rsquo;s shareholders of record at the close of business on the Record Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">A
shareholder whose Ordinary Shares are registered in his, her, or its favor with a member of a stock exchange and are included in
the Ordinary Shares which are registered in the register of shareholders of the Company under the name of such member of a stock
exchange, shall be required to prove ownership of such Ordinary Shares as of the Record Date by providing the Company, before the
time appointed for holding the Meeting, with proof of ownership, issued by a member of a stock exchange, or a copy of the shareholder's
Identification Card, passport, or Incorporation Certificate, if such shareholder is registered in the register of shareholders
of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>Legal Quorum</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the Articles, no business may be
transacted at any shareholders meeting unless a quorum is present when the meeting begins.&nbsp;The quorum required for a meeting
is the presence, in person or by proxy or by a voting deed, of at least two shareholders, holding in the aggregate at least one
third of the issued and outstanding Ordinary Shares as of the Record Date (&ldquo;<B>Quorum</B>&rdquo;).&nbsp;If within an hour
from the time appointed for holding a meeting a Quorum is not present, the meeting shall be dissolved and it shall stand adjourned
to the same day in the next week (or the business day following such day, if such day is not a business day) at the same time and
place and two shareholders then present at such adjourned meeting, in person or by proxy or by a voting deed, shall constitute
a Quorum.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Abstentions are counted in determining
if a Quorum is present.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>Proxy</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You can vote your shares by attending the
Meeting or by completing and signing a proxy card. Attached is the proxy card for the Meeting that is being solicited by our board
of directors. If you are voting by proxy, please follow the instructions on the proxy card. We encourage all shareholders to vote
by proxy, even if attending the Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are mailing copies of this invitation
and the proxy card to our shareholders of record as of the Record Date, and we will solicit proxies primarily by mail and e-mail.
The original solicitation of proxies by mail and e-mail may be further supplemented by solicitation by telephone, mail, e-mail
and other means by certain of our officers, directors and employees (who will not receive additional compensation for these services).
We will bear the cost of external solicitors and of the solicitation of the proxy cards, including postage, printing and handling,
and will reimburse the reasonable expenses of brokerage firms and others for forwarding material to beneficial owners of our Ordinary
Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will not be able to count a proxy card
unless we receive it, accompanied by a copy of (a) the shareholder's Identification Card, passport, or Incorporation Certificate
(if applicable), with respect to a shareholder who is registered in the register of shareholders of the Company, and (b) with proof
of ownership, as specified above, with respect to a shareholder whose shares are registered under the name of a member of a stock
exchange. We will not be able to count a proxy card unless we receive it at our principal executive offices at 37 Dereh Menachem
Begin St., Tel Aviv 6522042, Israel or at our transfer agent, Vstock Transfer, LLC, at 18 Lafayette Place, Woodmere, NY 11598 in
the enclosed envelope, by January 27, 2016 at 6:00 a.m. Israel time, which is January 26, 2016, at 11:00 p.m. Eastern standard
time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If you sign and return the enclosed proxy
card, your shares will be voted in favor of all of the proposed resolutions, whether or not you specifically indicate a &ldquo;FOR&rdquo;
vote, unless you specifically abstain or vote against a specific resolution. On all matters considered at the Meeting, abstentions
will be treated as neither a vote &ldquo;FOR&rdquo; nor &ldquo;AGAINST&rdquo; the matter, although they will be counted in determining
if a Quorum is present.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.35pt 0pt 146.35pt; text-align: justify; text-indent: 33.65pt">By
order of the Board of Directors,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.35pt 0pt 146.35pt; text-align: justify; text-indent: 33.65pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.35pt 0pt 146.35pt; text-align: justify; text-indent: 33.65pt"><U>/s/
Mr. Fredric Price</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.35pt 0pt 146.35pt; text-align: justify; text-indent: 33.65pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.35pt 0pt 146.35pt; text-align: justify; text-indent: 33.65pt"><U>Mr.
Fredric Price</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.35pt 0pt 146.35pt; text-align: justify; text-indent: 33.65pt">Executive
Chairman of the Board of Directors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.35pt 0pt 146.35pt; text-align: justify; text-indent: 33.65pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">December 22, 2015</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_002.jpg" ALT="" STYLE="height: 53px; width: 248px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>BIOBLAST PHARMA LTD.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TEL-AVIV, ISRAEL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>_____________________</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROXY STATEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>_____________________</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">This Proxy Statement
is furnished to the holders of ordinary shares, NIS 0.01 nominal value per share (&ldquo;<B>Ordinary Shares</B>&rdquo;), of BioBlast
Pharma Ltd. (&ldquo;<B>Company</B>&rdquo;) in connection with the solicitation by the board of directors of proxies for use at
the Extraordinary General Meeting of Shareholders, or at any adjournment thereof, pursuant to the accompanying Notice of Extraordinary
General Meeting of Shareholders. The meeting will be held on January 27, 2016, at 10:00 a.m. (Israel Time), at the offices of the
Company's counsel, Zysman, Aharoni, Gayer &amp; Co., at &quot;Beit Zion&quot;, 41-45 Rothschild Blvd., 8th Fl., Tel Aviv 65784,
Israel (&ldquo;<B>Meeting</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SOLICITATION OF PROXIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.15pt 0pt 0; text-align: justify">The agenda for the Meeting
is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.15pt 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify">Approval of amended terms of engagement with Dr. Megiddo.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">ITEM
1 &ndash;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9;APPROVAL OF SERVICE TERMS OF DR. DALIA MEGIDDO</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As disclosed in the Company&rsquo;s public
filings and publications, Dr. Megiddo, the Company&rsquo;s co-founder and a director, served as the Company's Chief Development
Officer (&ldquo;<B>CDO</B>&rdquo;). On March 18, 2015, the Company&rsquo;s shareholders approved an amendment to the terms of Dr.
Megiddo&rsquo;s engagement with the Company, including, among other things, that she will serve as the Company&rsquo;s CDO (instead
of Chief Executive Officer), and shall become an employee of the Company. However, recently the parties agreed that Dr. Megiddo
will transition her responsibilities as CDO to a newly hired executive, and shall serve as an advisor to the Chief Executive Officer
of the Company. In connection with the transition, the parties agreed that Dr. Megiddo shall provide services as a service provider,
and not an employee, to extend the period of time required to terminate her engagement without cause from 60 days to 6 months and
that such terms of engagement shall become effective retroactively as of January 29, 2015. The changes in Dr. Megiddo&rsquo;s previously
approved terms of engagement are set forth in <B><U>Exhibit A</U></B> attached hereto, which terms comply with the limitations
set forth in the Company&rsquo;s Compensation Policy. Adoption of Exhibit A shall not change the monthly cost to the Company in
engaging Dr. Megiddo.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 12, 2015 Dr. Megiddo stepped
down from the position of CDO and became an advisor to the Chief Executive Officer of the Company. Dr. Megiddo continues to serve
as a director on the Board of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">It is therefore proposed that the following
resolution be adopted at the meeting:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>RESOLVED,
</B>to approve the amended terms of engagement with Dr. Megiddo, as set forth in Exhibit A, effective retroactively as of January
29, 2015.</FONT>&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The affirmative vote of a majority of the
shares voting on the matter is required to approve this resolution, providing either (i) included in such majority is at least
a majority of the shares of shareholders who are non-controlling shareholders and do not have a personal interest in the said resolution
(excluding for such purpose any abstentions disinterested majority); or (ii) the total number of shares of shareholders specified
in clause (i) who voted against this resolution does not exceed two percent (2%) of the voting rights in the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The Company&lsquo;s board of directors
recommends that you vote &ldquo;FOR&rdquo; the proposal included in this Item.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I></I></B></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Exhibit A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>TERMS OF SERVICE</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following is a summary of the proposed
material amendments to Dr. Megiddo's current terms of service as approved by the Company shareholders on March 18, 2015:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<table cellspacing="0" cellpadding="0" style="border: #999999 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 21%; border: #999999 1pt solid; padding: 6.75pt">&nbsp;</td>
    <td style="width: 40%; border: #999999 1pt solid; padding: 6.75pt; text-align: center"><b>Current terms:</b></td>
    <td style="width: 39%; border: #999999 1pt solid; padding: 6.75pt; text-align: center"><b>Proposed Amended Terms:</b></td></tr>
<tr style="vertical-align: top">
    <td style="border: #999999 1pt solid; padding: 6.75pt"><b>Title and Status:</b></td>
    <td style="border: #999999 1pt solid; padding: 6.75pt">Chief Development Officer; an employee of the Company</td>
    <td style="border: #999999 1pt solid; padding: 6.75pt">Chief Development Officer, or, when directed by the Chief Executive Officer of the Company, an advisor to the Company; service provider</td></tr>
<tr style="vertical-align: top">
    <td style="border: #999999 1pt solid; padding: 6.75pt"><b>Term and Termination:</b></td>
    <td style="border: #999999 1pt solid; padding: 6.75pt">Either party may terminate the agreement without cause upon providing 60 days advance notice</td>
    <td style="border: #999999 1pt solid; padding: 6.75pt">Either party may terminate the agreement without cause upon providing 6 months advance notice</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Note: The monthly cost of the engagement
with Dr. Megiddo under the new arrangement does not change compared with the terms approved by the Company&rsquo;s shareholders
on March 18, 2015. In addition, the new terms shall become effective retroactively as of January 29, 2015, and shall override the
terms approved on March 18, 2015 to the extent they are not consistent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><B>BioBlast Pharma
Ltd.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><B>PROXY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">THIS PROXY IS SOLICITED
ON BEHALF OF THE BOARD OF DIRECTORS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The undersigned hereby
appoints Mr. Fredric Price, Executive Chairman of the Board, Mr. Colin Foster, President and Chief Executive Officer, Mr. Udi Gilboa,
Chief Financial Officer and Mr. Dan Riemer, Controller, and each of them, agents and proxies of the undersigned, with full power
of substitution to each of them, to represent and to vote on behalf of the undersigned all the Ordinary Shares of BioBlast Pharma
Ltd.&nbsp;(the &ldquo;<B>Company</B>&rdquo;) which the undersigned is entitled to vote at the Extraordinary General Meeting of
Shareholders (the &ldquo;<B>Extraordinary Meeting</B>&rdquo;) to be held at the offices of the Company's counsel, Zysman, Aharoni,
Gayer &amp; Co., at &quot;Beit Zion&quot;, 41-45 Rothschild Blvd., 8th Fl., Tel Aviv, Israel, on January 27, 2016, at 10:00 a.m.
(Israel time), and at any adjournments or postponements thereof, upon the following matters, which are more fully described in
the Notice of Extraordinary General Meeting of Shareholders and Proxy Statement relating to the Extraordinary General Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">This Proxy, when properly
executed, will be voted in the manner directed herein by the undersigned. If no direction is made with respect to any matter, this
Proxy will be voted FOR such matter.&nbsp;Any and all proxies heretofore given by the undersigned are hereby revoked.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>(Continued and
to be signed on the reverse side)</B></P>


<HR SIZE="3" NOSHADE ALIGN="LEFT" STYLE="width: 100%; color: black">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS
OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><B>BioBlast Pharma
Ltd.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><B>January 27, 2016</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">PLEASE SIGN, DATE
AND RETURN PROMPTLY IN THE ENCLOSED EVNELOPE. PLEASE MARK YOUR VOTE IN BLUE OR BLACK INK AS SHOWN HERE <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">To approve the amended terms of engagement
with Dr. Megiddo, as set forth in Exhibit A, effective retroactively as of January 29, 2015.</FONT>&rdquo;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 20%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; direction: ltr; unicode-bidi: embed"><font style="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Wingdings">&#168;</FONT></font></td>
    <td style="width: 16%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; direction: ltr; unicode-bidi: embed"><font style="font-family: Times New Roman, Times, Serif"><b>FOR</b></font></td>
    <td style="width: 16%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; direction: ltr; unicode-bidi: embed"><font style="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Wingdings">&#168;</FONT></font></td>
    <td style="width: 16%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; direction: ltr; unicode-bidi: embed"><font style="font-family: Times New Roman, Times, Serif"><b>AGAINST</b></font></td>
    <td style="width: 16%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; direction: ltr; unicode-bidi: embed"><font style="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Wingdings">&#168;</FONT></font></td>
    <td style="width: 16%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; direction: ltr; unicode-bidi: embed"><font style="font-family: Times New Roman, Times, Serif"><b>ABSTAIN</b></font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In their discretion, the proxies are authorized
to vote upon such other matters as may properly come before the Extraordinary Meeting or any adjournment or postponement thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>By signing this Proxy, the undersigned
hereby declares not to be a &ldquo;Controlling Shareholder&rdquo; or have a &ldquo;Personal Interest&rdquo;, as such terms are
defined in the Israeli Companies Law, 1999, with respect to any of the proposals above.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Note: Please contact the Company if you
have any questions or reservations with respect to the declaration above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 32%; padding: 0; text-align: justify; direction: ltr; unicode-bidi: embed; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">___________________</font></td>
    <TD STYLE="width: 32%; padding: 0; text-align: justify; direction: ltr; unicode-bidi: embed; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">___________________</font></td>
    <TD STYLE="width: 36%; padding: 0; text-indent: 0">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">____________, 201_</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; direction: ltr; unicode-bidi: embed; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">NAME</font></td>
    <TD STYLE="padding: 0; text-align: justify; direction: ltr; unicode-bidi: embed; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">SIGNATURE</font></td>
    <TD STYLE="padding: 0; text-align: justify; direction: ltr; unicode-bidi: embed; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">DATE</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 32%; padding: 0; text-align: justify; direction: ltr; unicode-bidi: embed; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">___________________</font></td>
    <TD STYLE="width: 32%; padding: 0; text-align: justify; direction: ltr; unicode-bidi: embed; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">___________________</font></td>
    <TD STYLE="width: 36%; padding: 0; text-indent: 0">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">____________, 201_</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; direction: ltr; unicode-bidi: embed; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">NAME</font></td>
    <TD STYLE="padding: 0; text-align: justify; direction: ltr; unicode-bidi: embed; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">SIGNATURE</font></td>
    <TD STYLE="padding: 0; text-align: justify; direction: ltr; unicode-bidi: embed; text-indent: 0"><font style="font-family: Times New Roman, Times, Serif">DATE</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Please sign exactly as your name appears
on this Proxy. When shares are held jointly, each holder should sign. When signing as executor, administrator, trustee or guardian,
please give full title as such. If the signed is a corporation, please sign full corporate name by duly authorized officer, giving
full title as such. If signer is a partnership, please sign in partnership name by authorized person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="margin: 0; text-align: right"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  U /@# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BHKBXAM
M('GGD6.-!EF8]*X#4/&5[JM\;+26^S0<EYR/FVCJ1Z4FU%7>PTFW9'H990<$
M@'ZTI.!D]*\L:^EB?='++(>\DS;F)]?:IK_Q;?6'AJ=)I<RS_NX&)^;GJ?H*
M\[#YKA\15]E3NWZ:';5R^M2I>UG9+UU,[QMXTN+_ %"33M/F,=G$=KLG_+0]
M_P *RO#>MW>AWJ2PR$PEOWD6>&%8-O:74[9B@E<]20IJY&&C;9(K*PZAABO2
M.$^@+:>.ZMHYXCE)%#*?:I:YWP1<FY\,0$G/EL8_RKHJ "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /+/'7B-KO47
MTV%\6]NV'P?O-6!H%T@U%XF(#31,B$]V]*PKN2X6\F6X!$X;YP?6J_F,&#!B
M"#D$=JSJTU4@X/9JQ4)N$E)=#UG1/#PU2TEF:;RY%;:H*[@"/45H_P#"!63R
M?:+B9KBXQC=*N5 ] O:L#P'XQMGN#97\BQ3R !7)PLA_H:],[9KCP.!AAZ/)
M;7JUU^9U8K%2K5.>^G1=CA=;T.73+02I?%T4@>60!CZ5S.I(+_39GDYFMT,B
MR=]HZK6WXCU**X\7MIZR;A):_)SP7["JVE:+<ZL'B52L+GRY7/&%[X]Z\JK0
MG1S*FZ%^66^K:\^YZ$*L:N!G[:UX^27H=5X%MV@\*6I88\W,@^AKD_$?B'Q!
M>>.&T/0[M8@%"X/ #=R37I<44=K:I%&H6.-,*!Z"O%-*TJ\\6>+]8N[.^:R9
M9&<RK[]J^E/#.B\.^*O$%IXQ7P_K,D5SN.TM'SM/KGTK7$FJ77Q&(@UN$V,2
MX>S63GCKE?7WKE/A_*FG^,=1L[M$N+E$=OM9.2NWKS[U6\)WCQW'B?Q&H)E@
MB;83_>8\?RH ]7U#Q)HVE3"&^U*W@D_NNW-6H]0MKC3VO+>=)8-A8.IR*\E\
M)>'=/UKP]JFO:U(TTA+_ #,_W2!U_E5?P??36?@KQ.QD80JH$.3QN.1Q0!8T
MO6?&OB3[=<V%_%'%:L2RN=N1S@#\JZ3P7XTO-6T75'U$*9+!<^<HP&X/Z\5P
M^F^&=0D\$W.M0:HUO&=Q>WS@.![^M:VDZI##\)M2\NW2*4MY+N/XR>_UIB-K
MX676H7_]IW=]=S3Q[PL?F-D#KFNONO%N@6,Y@N=6MHY1U4O7E9O[C0/AC9V]
MLYCGU.9V,@Z[/2H?$GA[3="\':>2?,U6\8.7+9P.X'YTAGLW]KZ=_9_V_P"V
M0_9#SYN[Y:JV?BG0]0,HM-3MYC$A=]K?=4=2:\[\1^&]2F\!Z$MC$TB6T>^X
MB0\G/.<?G5GPA<>'-2T?4MNF_9;J*U*7 5OOKCD@T :VG?$6&_\ %DVG,(8;
M"/<$N&?/F'MCZUVEY<?9[&:<'[B%@:\C^&GAFQUA[N\O8BZP2CR,-C!YZ_I7
MI?B:;R-#E XWD)6&*J>RH3GV3-:$/:58Q[M&';7FO7EI+>PW"^5&3D'O5Q==
MENO#5S*YV7"?)N7CKWJA86&M3Z6MO R1VLOS9/!.:DUJR32=$@L@VZ263<S>
MI%?,4ZF)A1=6\N7E=^9Z-O:WWGMRA1E45/2_-I;HEO<T= U."#3$%[>KYTC$
M@.W..U="74)O+#;C.<\5PFK:7!I^E69P?M,IRQ)JSJ\\[QZ?I*N5W1J7YZYZ
M5V8?,:N&INE5CK%1MKJV]D_,YZN#A6FITY?$W?T78Z4ZWI@?8;V+=G&,U8DO
M;:(H))T4ORN3UKB=:TZUM+RTLK8?O.-[$Y))J?7XFN==M;&(X(15!]*IYKB(
M*:E!-Q<5I?=]/D2L#2DX\LG9IO7LCJQJ=D5D87,9$9 <YZ&FOJVGQE UW$"X
MRO/6N;UZPM])TA+6#<6FD!8D]2*HZMID.GZ=8X!^T2\L2:=?,\52<DX1O%)O
M5]7L%+!4*G*U)^\VEMTZG:2:G8Q3"&2ZB60]%S5EY$C0N[!5'))-<'K.F0Z?
M!8*NXW$G,C$]>E7-9DEO=5M-)60K& H8YZDCO5?VK5ASJI!<RY4DGUET?ZD_
M4(2Y7"6CO=OLNIT8UO3"^W[;%NZ8S17):AI]JFO6UA:K\O"L<YR:**>/QU24
MHQA%\KL]6$\+AH*+<FKJ_0W=8\&:+KD_GW5N1,>KQMM)^OK6=#\-?#T/S&*9
MV'=I"1^5=A17NGEGDEW:6]K<R6QLK4HC?*PCP2/K6]!XIE@TDVD<;F7&U'=]
MQ ^M1>,;"XTNZ;44MVN+"0YD"_>B;U'M[5RDGB&RCC+6<,LLO\)F& I]?>OG
M:N%S2-5QI3O!]6]E_78]J&(P$J:E.%I+LMS/\33N-;C*.5F@B521U#"O4? G
MB./6])\EU1+NWXD51@-Z-7C,_G3S/-*Q:1SN9CW-=#X N9;7Q?:JF<39C<>Q
M[U[U.FH0C%=%8\B<W.3EW=SVRYC>:VEC1]CNI4-Z5YM!\*[VT,OV;Q!-")3\
M_EKC=]:].HK0@X_1O -IH>G7D=O<-)>W,9C-S(.0#Z"G^'? T&C:+?:=<SFY
M2\R)#MV\5UM% 'F ^%E]%YMI!KTL>G2MEXP.H]Q70WO@2V?PB-!L)S;J9%D>
M4C)<CKGZUUU% 'F:?"NZ,*VLOB"<V@.?*"\?E6SJ?P_MKCPQ#H=A<&VA642N
MQ&XNWO79T4 <;K/@&'5/#-AI:W!CFL5Q'+C.?7(]ZQ)/A3-<VT/VG6I9+A"!
MEER%4= *]-HH XK7?"&L7UW%/IVO36:+"L)B3@<=ZDT'P#;:-I=_;O=/-<7R
M%))<8P/85V-% '#^$/ MUX8U66X;4FEMRI41 8!SW/O72ZUI3:M D0F\M5;)
MXSFM.BLZU*%:#IS5TRZ=25.2G'=$-K +:UB@4Y"*%S6;K&B'5;B!S/L2+^'&
M<UL45%7#TZM/V4U[NGX%0K3A/VD7J8VKZ&=4EMR9]B1?PXZTS6/#XU&6.>*;
MRI4 7..H%;E%95,!AZG-S1^*U_EL7#%U8<O*]KV^>YS<7A8QWL-RUVSNC!G+
M#.XU<70S_;IU)YL\Y"8Z5L45,,NPT-(QZWW>Z*EC*TMWTM\C(UC13JT\#F?8
ML7\.,YINIZ&=1N[>4S;4BQ\N.M;-%7/ T)N3DOBLW\MB8XJK&R3VO;Y[F/J&
MAF_U&"Y:;"18^3'6H=5\.F^O5N[><PR8 /'IWK>HJ:F7X>HI*4?B=WZH<,76
MA:SV5CGK7PP+74HKL73.4.6W#EC170T5KA\+2PZ<:2LGJ9U:\ZS3F[V"BBBN
M@R&NBR(R.H96&"",@UQ>M^ -+D66[M6>U(&XH@RI_P *** //+FQ2*Z$ 8D9
MQG%>C^#?"5EIJKJF]IKB1<*6& @]J** .RHHHH **** "BBB@ HHHH ****
C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  U /@# 2(  A$! Q$!_\0
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? "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
